Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Polynovo ( (AU:PNV) ) has provided an update.
PolyNovo announced a special briefing hosted by Bell Potter featuring Professor Toby Coates, who successfully used PolyNovo’s NovoSorb in a pancreatic islet transplant for a long-term Type 1 diabetic. This marks a new market entry for NovoSorb, showcasing its versatility and potential impact on the medical field, particularly in islet cell transplantation.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. Their flagship product, NovoSorb, is a bio-resorbable polymer used for dermal regeneration, which has treated over 70,000 patients in 46 countries. The company is focused on growth through new products, indications, and market expansion.
YTD Price Performance: -44.12%
Average Trading Volume: 2,087,005
Technical Sentiment Signal: Sell
Current Market Cap: A$787.6M
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.